Document is current
Any future updates will be listed below
-
Authors
Zhang, Huanhuan
Wang, Ruolan https://orcid.org/0009-0009-1538-3503
Shi, Pan
Wang, Gaoming
Zhu, Qingjun
He, Xinheng https://orcid.org/0000-0001-7813-5480
Xu, Youwei https://orcid.org/0000-0001-8069-7511
Yuan, Qingning
Hu, Wen
Wu, Kai
Zheng, Yong
Zhou, Li
Liang, Jun
Lv, Pei
Xu, Ziyan
Yang, Fan
Liu, Yingbin https://orcid.org/0000-0001-6110-0185
Zhuang, Youwen https://orcid.org/0000-0002-1380-8047
Xu, H. Eric https://orcid.org/0000-0002-6829-8144
Wang, Yue https://orcid.org/0000-0002-3716-2922
Tian, Changlin https://orcid.org/0000-0001-9315-900X
-
Funding
Funding for this research was provided by:
National Natural Science Foundation of China (22437005)
- License Information
-
More Information
Article History
Received: 9 September 2025
Accepted: 13 March 2026
First Online: 14 April 2026
Competing interests
: H.E.X is a founder of Cascade Pharmaceutics. C.T. is a founder of Hefei KS-V Peptide Biological Technology Co. Ltd.; All the other authors declare no other competing interests.
